Characteristics associated with disease progression in patients with transthyretin amyloid cardiomyopathy treated with tafamidis

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Dr. Gaggin has received research grant support from Roche Diagnostics, Pfizer, Alnylam, AstraZeneca, Akcea (IONIS), Eidos/BridgeBio, eMyosound; consulting income from Alnylam, AstraZeneca, BridgeBio, eMyosound, Merck, Novo Nordisk, Pfizer, TD Cowen; Stock - Dr. Gaggin has received research grant support from Roche Diagnostics, Pfizer, Alnylam, AstraZeneca, Akcea (IONIS), Eidos/BridgeBio, eMyosound; consulting income from Alnylam, AstraZeneca, BridgeBio, eMyosound, Merck, Novo Nordisk, Pfizer, TD Cowen; Stock</li></ul>